Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomonori Araki

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Cureus|February 24, 2025
Drug-Induced Chylothorax During Chemotherapy With Ramucirumab and Paclitaxel for Advanced Gastric CancerKenichi Sawa, Kohei Hayashi, Yuki Sonoda, et al.
Internal Medicine (Tokyo, Japan)|August 28, 2018
Rectal ParagangliomaTomonori Araki, Shigeyuki Takeshita, Hiroko Kawasaki, et al.
DEN Open|July 20, 2023
Dabigatran-induced esophagitis with full circumferential blue pigmentationTomonori Araki, Kohei Hayashi, Yuki Sonoda, et al.
Cancers|September 9, 2022
Enhanced Cytotoxicity on Cancer Cells by Combinational Treatment of PARP Inhibitor and 5-Azadeoxycytidine Accompanying Distinct Transcriptional ProfilesTomonori Araki, Kensuke Hamada, Aung Bhone Myat, et al.
General Thoracic and Cardiovascular Surgery Cases|November 9, 2024
Long-term survival after conversion surgery for an esophageal neuroendocrine carcinoma: a case reportTakahiro Enjoji, Shinichiro Kobayashi, Kohei Hayashi, et al.
Anti-Cancer Drugs|June 25, 2016
Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tractTomonori Araki, Atsuo Takashima, Tetsuya Hamaguchi, et al.
Cancers|April 30, 2020
Reduced Tumorigenicity of Mouse ES Cells and the Augmented Anti-Tumor Therapeutic Effects under <i>Parg</i> DeficiencyYuki Sonoda, Yuka Sasaki, Akemi Gunji, et al.
Therapeutic Advances in Medical Oncology|February 24, 2025
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302)Tomonori Araki, Kohei Hayashi, Mototsugu Shimokawa, et al.
International Journal of Cancer|August 1, 2025
Chemotherapy-induced neutropenia predicts short-term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acidTomonori Araki, Tsuyoshi Shirakawa, Mototsugu Shimokawa, et al.
Scientific Reports|January 27, 2025
Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301)Tomonori Araki, Yuki Sonoda, Mototsugu Shimokawa, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cureus|February 24, 2025
Drug-Induced Chylothorax During Chemotherapy With Ramucirumab and Paclitaxel for Advanced Gastric CancerKenichi Sawa, Kohei Hayashi, Yuki Sonoda, et al.
Internal Medicine (Tokyo, Japan)|August 28, 2018
Rectal ParagangliomaTomonori Araki, Shigeyuki Takeshita, Hiroko Kawasaki, et al.
DEN Open|July 20, 2023
Dabigatran-induced esophagitis with full circumferential blue pigmentationTomonori Araki, Kohei Hayashi, Yuki Sonoda, et al.
Cancers|September 9, 2022
Enhanced Cytotoxicity on Cancer Cells by Combinational Treatment of PARP Inhibitor and 5-Azadeoxycytidine Accompanying Distinct Transcriptional ProfilesTomonori Araki, Kensuke Hamada, Aung Bhone Myat, et al.
General Thoracic and Cardiovascular Surgery Cases|November 9, 2024
Long-term survival after conversion surgery for an esophageal neuroendocrine carcinoma: a case reportTakahiro Enjoji, Shinichiro Kobayashi, Kohei Hayashi, et al.
Anti-Cancer Drugs|June 25, 2016
Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tractTomonori Araki, Atsuo Takashima, Tetsuya Hamaguchi, et al.
Cancers|April 30, 2020
Reduced Tumorigenicity of Mouse ES Cells and the Augmented Anti-Tumor Therapeutic Effects under <i>Parg</i> DeficiencyYuki Sonoda, Yuka Sasaki, Akemi Gunji, et al.
Therapeutic Advances in Medical Oncology|February 24, 2025
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302)Tomonori Araki, Kohei Hayashi, Mototsugu Shimokawa, et al.
International Journal of Cancer|August 1, 2025
Chemotherapy-induced neutropenia predicts short-term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acidTomonori Araki, Tsuyoshi Shirakawa, Mototsugu Shimokawa, et al.
Scientific Reports|January 27, 2025
Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301)Tomonori Araki, Yuki Sonoda, Mototsugu Shimokawa, et al.
Pageof 2